Skip to main content
Sign In
 

Thomas W. Flaig, MD

Associate Professor, Division of Medical Oncology. Associate Dean for Clinical Research, University of Colorado School of Medicine


 Flaig Photo

Education:  MD

University of Minnesota, June 1999

Dr. Flaig completed his fellowship in 2006 at the University of Colorado Denver, after which he joined the faculty of the Divison of Medical Oncology at the University of Colorado Denver, Aurora, CO.

Research
Dr. Flaig is focused on translational genitourinary cancer research. He is a graduate of the University of Minnesota School of Medicine and completed the hematology/oncology fellowship program at the University of Colorado in 2006. The GU oncology clinic actively participates in cooperative (SWOG) and industry-sponsored clinical trials. His laboratory effort is split between new prostate cancer treatment approaches using natural products and the integration of targeted therapies into the treatment of bladder cancer, in addition to an active clinical practice treating all types of urologic cancers. 

Publications

  1. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.   Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ.   J Clin Oncol. 2016 Aug 20;34(24):2835-42. doi: 10.1200/JCO.2016.67.4788.  PMID: 27325855

  2. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.   de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PF, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW.   Eur Urol. 2016 Jul 8. pii: S0302-2838(16)30385-2. doi: 10.1016/j.eururo.2016.06.033. [Epub ahead of print]  PMID: 27402060

  3. Functionalized gold nanorods for thermal ablation treatment of bladder cancer.  Cho SK, Emoto K, Su LJ, Yang X, Flaig TW, Park W.   J Biomed Nanotechnol. 2014 Jul;10(7):1267-76.   PMID: 24804547

  4. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia.   Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, Degregori J, Serkova NJ, Li Y, Su LJ, Kessler E, Flaig TW.  PLoS One. 2013 Sep 18;8(9):e74809. doi: 10.1371/journal.pone.0074809.  PMID: 24058630

  5. Abiraterone in metastatic prostate cancer without previous chemotherapy.   Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators.  N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.   PMID: 23228172

  6. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.  Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW.  Clin Cancer Res. 2013 Jan 1;19(1):148-57. doi: 10.1158/1078-0432.CCR-12-1258.  PMID: 23172881 

  7. Increased survival with enzalutamide in prostate cancer after chemotherapy.   Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators.  N Engl J Med. 2012 Sep 27;367(13):1187-97.   PMID: 22894553

  8. miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2.  Yang X, Bemis L, Su LJ, Gao D, Flaig TW.   Biores Open Access. 2012 Apr;1(2):55-62. doi: 10.1089/biores.2012.9903.  PMID: 23514806

  9. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.   Flaig TW, Wilson S, van Bokhoven A, Varella-Garcia M, Wolfe P, Maroni P, Genova EE, Morales D, Lucia MS.   Urology. 2011 Oct;78(4):863-7. doi: 10.1016/j.urology.2011.05.045.   PMID: 21813167

  10. Abiraterone and increased survival in metastatic prostate cancer.   de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.  N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.   PMID: 21612468

  11. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.   Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glodé LM; Southwest Oncology Group.  J Clin Oncol. 2008 Mar 20;26(9):1532-6. doi: 10.1200/JCO.2007.13.4197.  PMID: 18349405

  12. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.   Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT.   BJU Int. 2009 Jun;103(12):1729-37. doi: 10.1111/j.1464-410X.2009.08367.x.  PMID: 19220256

  13. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM. Invest New Drugs. 2007 Apr;25(2):139-46.   PMID: 17077998​



PubMed Articles